FDA ACCEPTS JAZZ’S NDA FOR DEFIBROTIDE UNDER PRIORITY REVIEW
Jazz Pharmaceuticals’ New Drug Application for defibrotide for hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with evidence of multi-organ dysfunction (MOD) following hematopoietic stem-cell transplantation (HSCT), has been accepted by the U.S. Food and Drug Administration with Priority Review.
JAZZ IN THE NEWS
CEO Bruce Cozadd interview with Life Sciences Leader: “From Foundation, To Darkest Days, To Finest Hour — The Jazz Pharmaceuticals Success Story.”
JZP-110 PHASE 3 CLINICAL PROGRAM STARTS
JZP-110 is an investigational wake-promoting agent being developed as a treatment for EDS in adult patients with narcolepsy or with OSA. Jazz has worldwide rights to JZP-110, excluding certain jurisdictions in Asia where SK Biopharmaceuticals Co., Ltd retains rights.